Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

NutriSystem Inc. (NTRI): Medical Food

NutriSystem IncEating right makes you healthier. That might sound simplistic, but Nestle, Danone, and NutriSystem Inc. (NASDAQ:NTRI) are taking that idea to a whole new level. And there’s money to be made along the way.

You are what you eat

It’s simple logic that eating healthier foods can help you feel better. However, many people just don’t eat the way they should. Thus, lifestyle-related illnesses like obesity and diabetes run rampant. High blood pressure, strokes, and heart attacks have material lifestyle components, too.

Physicians have been trying to get patients to change for years.  Now food companies are joining the fray, and their timing may be just about perfect. First, the baby boomer generation is heading toward retirement and their peak medical use years. Second, the U.S. government is stepping into the health care market in a big way. Preventative medicine will likely become increasingly important as a tool to keep costs down and people healthier.

A Food Giant

Nestle is a giant in the packaged food industry. However, the company has begun to push the boundaries of what is food and what is medicine. In 2011, the company created the Nestle Health Science division. While still small, acquisitions and partnerships have been used to quickly build the business.

In 2012, the company purchased a stake in Accera (dietary management of Alzheimer’s disease), created a joint venture with Chi-Med (nutritional and medicinal products derived from plants), and bought Wyeth Nutrition from Pfizer (infant nutrition). One of its more recent purchases was of Pamlab, which essentially makes prescription vitamins for diabetic peripheral neuropathy, depression, schizophrenia, pregnancy, and mild cognitive impairment.

A Tough Quarter

The first quarter was a tough one for the Health Sciences division, with reimbursement issues and new competitors in key markets taking shelf space from core brands. That said, this group isn’t the one driving performance today. Emerging markets, which account for about 45% of the top line, are the most notable contributors at Nestle. The emerging market push, then, should provide ample time for the nutrition division to establish itself.

The shares recently yielded around 2.5% and have been on a slow and steady ascent. The top and bottom lines can be a little volatile at this foreign company, as can the dividend payment, but it is a world leader in packaged foods and is a relatively safe way to play the push toward medicinal food.

Not Just Yogurt Anymore

Danone is a yogurt giant. In addition to yogurt and milk products (which account for about half of the top line), however, it also sells baby food, water, and products made by its “clinical nutrition” unit.

One of the most obvious medicinal products that Danone sells is Activa. This yogurt is specifically designed to help digestion and shows the impact of medicinal foods across the company’s product portfolio. However, the clinical nutrition division, which represents less than 10% of sales today, makes formula for infants allergic to cow milk, supplements for children not growing properly, and foods to help the elderly avoid things like age related muscle loss. Products for the elderly make up around half of the division’s sales.